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Abstract: Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical
carcinoma. Monitoring of plasma mitotane concentrations is recommended, but we do not know what
impact target concentrations have on patient outcome. To answer this question, we retrospectively
analyzed patient records in the Lysosafe Online® database (HRA Pharma, France) for patients who
were treated for≥6 months and who had≥3 measurements of plasma mitotane levels during follow-ups
at 11 tertiary centers in Italy from 2005 to 2017. We identified 110 patients treated with adjuvant
mitotane for a median of 46 months (IQR, interquartile range, 28–62) with a median maintenance
dose of 2.0 g/day (IQR 1.5–2.5). Achievement of target mitotane concentrations (≥14 mg/L) required
a median of 8 months (IQR 5–19). Female sex was associated inversely with the dose, while body
mass index (BMI) was correlated positively. Multivariate analysis showed that the Ki67 index and
time to achieve the target range of plasma mitotane were independent predictors of recurrence-free
survival (RFS). In a separate multivariate model, considering only the maintenance phase (month 7 to
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month 36, M7–M36) of treatment, the time in the target range of plasma mitotane was associated with
a significantly lower risk of recurrence (Hazard Ratio, HR = 0.93; 0.88–0.98, p < 0.01). The prognostic
implications of the time in target range and the time needed to reach target mitotane concentrations
support the use of mitotane monitoring and may inform practice.
Keywords: adrenocortical carcinoma; mitotane; prognosis; recurrence; survival
1. Introduction
Treatment of adrenocortical carcinoma (ACC) is based on surgery that is usually the first and most
effective therapeutic strategy [1–4]. Complete removal of the tumor may lead to a cure; however, ACC
has a strong propensity to recur after surgery, even when R0 (free resected margins) operations are
completed by skilled surgeons [5]. Therefore, the European Society of Endocrinology (ESE) - European
Network for the Study of Adrenal Tumors (ENSAT) guidelines on management of ACC indicate
adjuvant mitotane treatment for patients at high risk of recurrence, although they recognize a low level
of evidence, based only on retrospective, non-randomized studies [6]. It is recommended to regularly
monitor plasma mitotane levels during treatment with the aim of maintaining levels >14 mg/L [6],
based on studies suggesting a link between high mitotane levels and drug efficacy [7–9]. However,
the evidence supporting a target range when mitotane is used as an adjuvant measure is limited and
conflicting [8,10], and this may be due to the challenge in assessing the optimal exposure to mitotane
in chronic treatments.
To evaluate whether plasma mitotane concentrations have prognostic implication in ACC patients
on adjuvant mitotane treatment, we reviewed retrospectively the experience of 11 tertiary centers for
the care of ACC patients in Italy, adopting a novel method to assess target mitotane concentrations.
2. Experimental Section
For this study, we invited 13 tertiary centers for the care of ACC patients in Italy. Eleven centers
accepted the invitation to participate in the survey, providing clinical, pathological, and biochemical
data of all ACC patients who had been proactively followed at the center and treated with adjuvant
mitotane. We retrieved data of patients who were treated from July 2005 to July 2015. Follow up for
this study was closed in December 2017. The institutional ethics committee of all centers approved the
study, and all patients signed written informed consent (for patients under 18 years-of-age, parental
written consent was provided).
Inclusion criteria of the study were as follows: age ≥16 years, pathologically confirmed diagnosis
of ACC, complete macroscopic resection, availability of pre-operative and post-operative computed
tomography (CT) or magnetic resonance imaging (MRI) scans, complete follow-up information,
treatment with mitotane (all patients received the same mitotane formulation, Lysodren® 500 mg
tablets) for ≥6 months and with ≥3 measurements of plasma mitotane concentrations reported on the
Lysosafe Online® database. Exclusion criteria were as follows: incomplete tumor staging, history of
other previous or concomitant malignancies, R2 (macroscopic invasion of resected margins) resection,
incomplete follow-up information, concomitant adjuvant chemotherapy and radiotherapy or both,
and concomitant treatment with any drug specifically directed against ACC.
Patients’ charts were reviewed and the following information was retrieved for the study: gender,
age, body mass index (BMI), date of diagnosis, hormone secretion, ACC stage, pathology report, date of
recurrence, last follow-up or death. Date of diagnosis was defined as the date of surgery. Biochemical
confirmation of hormone excess was requested to categorize an ACC as hormone secreting. Tumor
stage was established according to the ENSAT classification (I and II, confined tumor; III, positive lymph
nodes or infiltrating neighboring organs/veins without distant metastases; IV, distant metastases [11].
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Date of recurrence was defined as the date of radiological evidence of a new lesion. A questionnaire
was sent to the participating centers to retrieve the information requested for the study; moreover, centers
were asked about indications, timing of initiation and discontinuation, reasons for discontinuation and
dose regimen of adjuvant mitotane treatment, and follow-up modality. The schedule of follow-up visits
was similar between centers, with an early assessment between 3–6 weeks after treatment initiation
including physical exam, plasma mitotane monitoring, and biochemical work-up. Evaluations were
afterwards scheduled every 3–4 months with physical exam, full body imaging, plasma mitotane
monitoring, and biochemical work-up for at least 3 years. After this time limit, timing of the follow-up
visits was individualized according to the preferences of the patients and physicians. Duration of
treatment was calculated from the date of initiation of mitotane therapy until ACC recurrence, or
discontinuation of treatment, or the end of follow-up, whichever occurred first.
For the analysis of plasma mitotane concentrations, we separately considered the first six months
of therapy (M0–M6) because this is the period when mitotane dose is progressively increased to attain
target levels and, as a consequence, mitotane concentrations are highly variable. During the first six
months, we analyzed the correlation between mitotane concentrations and the month of therapy and
drug dose. We considered the period from month 7 to month 36 (M7–M36) as the maintenance phase,
because mitotane dose is usually stable in chronic treatment. We set the time point at the 36th month,
since the timing of follow-up visits was more consistent between centers during this period. In a
multivariate regression analysis, we assessed the correlation between plasma mitotane concentrations
recorded during M7–M36 and patient sex, age, and BMI. We also calculated the time in target range
(TTR) during M7–M36, defined as the number of months in which mitotane concentrations were
≥14 mg/L, a value considered as the lower limit of the target range [7–9], for all patients. Based on the
concept of the “time in therapeutic range” used for monitoring warfarin therapy [12], we assumed that
a linear relationship existed between consecutive values when a measurement was not available.
Mitotane concentrations were retrieved from the Lysosafe Online® database, available at www.
lysosafe.com. Lysosafe Online® is a login-protected website that stores mitotane plasma concentrations
of patients treated by physicians who have registered with the Lysosafe® service, a free-of-charge
service of measurement of plasma mitotane concentrations in ACC patients offered by HRA Pharma to
European prescribers since 2005 and associated with the use of Lysodren®. Samples are collected at
the centers, sent to a centralized laboratory, extracted by precipitation with ethanol, and tested by a
standardized gas chromatography/mass spectrometry method. Plasma mitotane values of any patient
are available for the treating physician on www.lysosafe.com, in a historical and graphic plot that
matches mitotane levels with the relative Lysodren® dose. Patient data are anonymous during the
whole process since patients are recorded using an acronym and their date of birth.
All communication concerning the study between centers was by email, and a meeting was
organized to make the process of data capture more homogeneous.
Categorical data are presented as counts and percentages. Continuous data are presented as
medians and interquartile ranges (IQR). Differences in categorical variables were analyzed by means
of the chi-squared test or Fisher test as appropriate, while differences in continuous variables were
analyzed by the Mann–Whitney U test. Correlation analyses were determined by calculating the
Spearman’s R coefficient. Multiple regression analysis was done as appropriate. The survival curves
were estimated with the Kaplan–Meyer product limit method. Recurrence-free survival (RFS) was
calculated from the time of initial surgery to the first radiological evidence of recurrence. Overall
survival (OS) was calculated from the date of initial surgery to the date of death. Patients who did not
experience either of those events (recurrence or death) were censored at the date of the last follow-up
visit for the specific survival analysis. Cox proportional hazards regression models were fitted to
determine prognostic factors on RFS and OS. The following potential predictive factors for either
RFS or OS were investigated: patient sex and age, tumor stage, hormone secretion, Weiss score, Ki67
index, and the time elapsed to get the first plasma mitotane level at target. Stratification of patients
into risk groups was achieved through the maximally-selected log-rank statistics approach, which
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provides the value of a cut-off point corresponding to the most significant relation with outcome [13].
We did a second multivariate analysis to assess whether the TTR of mitotane concentrations between
M7 and M36 was an independent factor influencing RFS or OS. All reported p values are two-sided.
The p values less than 0.05 were considered as statistically significant. The statistical analyses were
performed with Statistica (StatSoft) (Dell Software, Round Rock, Texas, USA) and R version 3.5.1
(R Core Team, USA).
3. Results
From a total of 402 ACC patients on the Lysosafe® Online database, 110 patients fulfilled
inclusion/exclusion criteria and were retrospectively included in the study (Figure 1). Baseline
characteristics of patients are reported in Table 1.
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Figure 1. Study cohort.
Table 1. Baseline features of patients. IQR = interquartile range. BMI = Body Mass Index.
Characteristics Valid Cases (N) Values
Gend r, N (%) 110
Male 43 (39.1%)
Female 67 (60.9%)
Age at diagnosis, year 110
Median (IQR) 47 (35–58)
BMI, kg/m2 95
Median (IQR) 24.7 (21.9–29.4)
Tumor stage, N (%) 110
Stage I 11 (10%)
Stage II 80 (72.7%)
Stage III 17 (15.5%)
Stage IV 2 (1.8%)
Hormone secretion, N (%) 106
Yes 58 (54.7%)
No 48 (45.3%)
Weis score 90
Median (IQR) 6 (5–7)
Ki67 95
Median (IQR) 17 (6.5–30)
≤10% 32 (33.7%)
>10% 63 (66.3%)
The median follow-up was 63 (39–94) months. Adjuvant mitotane treatment was initiated after a
median time of 1 (1–2) month from the first surgery in 102 patients (92.7%) and after surgical treatment
of a recurrence in eight patients (7.3%). Median duration of treatment was 46 (28–62) months. The
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adjuvant therapy was discontinued permanently in 59 cases (53.6%), of which 36 (61.0%) were for end
of treatment after a median time of 58 (45–62) months. Other causes of treatment discontinuation were
toxicity (n = 5), patient’s decision (n = 4), concomitant diseases (n = 3), or other/not available data
(n = 11). Characteristics of mitotane treatment at the time of permanent discontinuation for toxicity are
reported in Table 2. Gastrointestinal symptoms included nausea and diarrhea, whereas neurological
manifestations were dizziness and confusion.
Table 2. Characteristics of mitotane treatment at the time of permanent discontinuation for toxicity.
Legend: GI = gastrointestinal, NEU = neurological.
Patients Mitotane Levels(mg/L)
Mitotane Dose
(g/Day)
Duration of Treatment
(Months) Type of Toxicity
1 12.7 1.5 23 GI
2 13.2 2.0 45 GI
3 9.2 1.5 31 NEU
4 10.6 2.5 19 NEU
5 12.4 2.5 18 GI/NEU
Median
(IQR)
12.4
(10.6–12.7)
2.0
(1.5–2.5)
23
(19–31)
All centers reported recommending adjuvant mitotane treatment in all ACC patients following
operation, with the exception of three centers, where treatment was offered to high-risk patients only.
All centers but one reported using a low-dose regimen with minimal variations in the starting dose
(1–2 g/day), while the velocity of further dose increments varied among centers. Maintenance dose
was guided by results of mitotane monitoring and patient tolerability.
During the period M0–M7, plasma mitotane levels increased progressively, being significantly
correlated with month of therapy (r = 0.6, p < 0.0001) and mitotane doses (r = 0.13, p < 0.034).
Achievement of target mitotane levels required a median time of 8 (5–19) months from start of therapy,
while 11 patients (10%) never achieved levels ≥14 mg/L.
The median mitotane dose in the maintenance phase was 2.0 (1.5–2.5) g/day. In a multiple
regression analysis, sex (β = -0.23, p = 0.02) and BMI (β = 0.22, p = 0.02) were correlated with median
doses of mitotane, implying that female sex was associated inversely with the dose, while BMI was
correlated positively. In the group of 102 patients who started adjuvant mitotane therapy after the
first surgery, recurrence occurred in 39 (38.2%) of cases. Median RFS was not reached, and the median
follow-up time for RFS was 54 months (27–78). Multivariate analysis showed that the Ki67 index and
time to the first mitotane level at target were independent predictors of RFS (Table 3).
Table 3. Univariate and multivariate analysis of predictive factors for recurrence-free survival (RFS).
HR = Hazard Ratio. The bold indicates the statistically significant values.
Title Univariate Analysis Multivariate Analysis
Factor HR 95% CI p Value HR 95% CI p Value
Gender 1 1.35 0.71–2.54 0.358 - - -
Age at diagnosis 1.10 0.67–1.80 0.709 - - -
Tumor stage 2 2.17 1.03–4.59 0.042 - - -
Hormone
secretion 3 0.79 0.42–1.52 0.486 - - -
Weiss score 1.60 1.03–2.48 0.038 - - -
Ki67 index 1.49 1.06–2.10 0.023 4.49 1.57–12.84 0.005
Time to first level
at target 1.22 1.00–1.50 0.053 1.48 1.06–2.07 0.020
Reference categories: 1 Male gender, 2 Stage III–IV, 3 Non-secreting tumors.
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We identified a cut-off value for the Ki67 index at 10% and for time to reach target mitotane
concentrations at 17 months, which were able to differentiate significantly patients for their risk of
recurrence (Figures 2 and 3).
In a separate multivariate model considering only the maintenance phase (M7–M36) of treatment,
TTR was associated with a significantly lower risk of recurrence (Hazard Ratio, HR = 0.93; 95% CI,
0.88–0.98; p < 0.01). Death occurred in 22 cases (20%). Median OS was not reached, and the median
follow-up time for OS was 70 months (49–100). We did not find any predictor of the risk of death due
to the low number of events.
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4. Discussion
The present study confirms that a remarkable number of patients with ACC who are operated on
with radical intent are destined to relapse [2,5,14–18]. ACC recurrence portends a worse prognosis
and has a huge impact on quality of life; therefore, investigators have considered the use of adjuvant
mitotane the apy following surgical operation. However, a limited number of often small-sized studies
reporting the outcome of adjuva t mitotane is available [19–22].
In the pres nt study, we explored the relati nship between target mitotane concentrations and
patien outcome using the TTR, analogous to warfarin treatment [12]. Some previous studie used th
peak mitotane level, which annot give an adequate representation since it is a measurement at a single
point in time [7]. I other studies, the percentage of mitotane measurements in range was used, but
this meth d has the caveat of being str ngly dependent on the number of available mea rements.
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This may introduce a bias when comparing patients with different durations of follow-ups, which
may be quite prolonged in the case of adjuvant therapy. Moreover, there is no evidence to define
what percentage level identifies a good exposure to mitotane. These methodological issues may have
contributed to the discrepancy in the literature concerning adjuvant treatment [8,10]. In the present
study, we calculated the TTR, which in our opinion gives a more adequate representation of chronic
exposure to mitotane, and analyzed the results in a multivariate analysis without predefining arbitrary
cutoff values. We found an inverse relationship between the TTR and risk of ACC recurrence, implying
that the greater the TTR, the lower the risk. This finding supports the clinical value of mitotane
monitoring and the concept of target doses in the adjuvant setting [6]. Although it is plausible that
lower mitotane concentrations may be effective in an adjuvant treatment, we analyzed only the level of
14 mg/L, because this was the target in our practice.
The time needed to achieve target mitotane concentrations also has an impact on the risk of ACC
recurrence: a longer time was associated with higher risk. This is consistent with the concept that
mitotane is a slow-acting drug in relation to the achievement of significant plasma levels. Due to the
very cautious dose titration in the starting phase of treatment employed in many centers, the time
needed to get into the target range was exceedingly long. We identified a time point at 17 months to
achieve target concentrations, which significantly differentiates patients for their risk of recurrence.
The present findings call for a change in practice, aiming for a faster rise in mitotane levels and
strengthening the value of mitotane monitoring. However, the potential danger of a rapid increment
in mitotane dosing, which may result in important toxicity with consequent loss of compliance to
treatment, should be considered [20].
We found only a weak relationship between mitotane dose and its plasma concentrations during
the first phase of treatment, and this finding is in agreement with the concept that individual differences
in mitotane metabolism and other still unknown factors influence plasma concentrations [23,24].
Interestingly, higher doses were employed in men and in patients with greater BMI and these novel
findings matter for clinical practice.
In our cohort, toxicity associated with adjuvant mitotane was acceptable, though we acknowledge
the fact that due to the study inclusion criteria we did not capture the patients who eventually
discontinued mitotane in the first six months. Severe toxicity leading to permanent treatment
discontinuation was recorded in only five patients on chronic therapy, and this is likely due to the
low doses (median dose of 2 g/day) used to continue treatment in the maintenance phase. Thus, the
present study shows that a few patients cannot tolerate adjuvant mitotane following the first months
of treatment, proving than a careful follow-up is necessary. Despite mitotane having a reputation
for being a challenging drug to manage [17], adjuvant mitotane treatment is feasible when patients
are managed in expert centers. However, some patients were unable to tolerate the drug, exhibiting
neurological toxicity even when exposed to “normal” mitotane concentrations, confirming the relevance
of individual factors in mitotane metabolism.
Strengths of the present study are the thorough characterization of adjuvant mitotane treatment
of ACC patients following surgical removal of the tumor and the large data set, considering the rarity
of the disease. This allowed for the capture of details of mitotane treatment that were not available in
previous studies and led to observations that may be useful to informing future practice. However, we
should acknowledge the limits of a retrospective analysis, and that our results are not generalizable to
patients who discontinue treatment within six months for intolerability or patients with early ACC
recurrence. The inclusion criteria of the study produced an immortal time of six months that may have
enriched our series of a higher number of low-risk ACC compared to recently published series [10,25].
5. Conclusions
In conclusion, a low-dose mitotane regimen is generally well tolerated but has the drawback of
needing quite a long time to reach the target concentrations. The observation that the TTR of mitotane
and the time to the first level in range are associated to the risk of recurrence is novel and has practical
J. Clin. Med. 2019, 8, 1850 8 of 9
importance. Thus, the use of mitotane monitoring and the value of target mitotane concentrations are
justified by this analysis of real practice.
Author Contributions: Conceptualization, S.P., G.R. and M.T. (Massimo Terzolo); Data curation, V.B., F.C., C.S.
(Carla Scaroni), C.S. (Chiara Simeoli), M.T. (Massimo Torlontano), S.C., G.A., A.S., P.M., B.A., S.D.C., G.D.F.,
L.C. and P.L.; Formal analysis, S.P. and M.T. (Massimo Terzolo); Funding acquisition, M.T. (Massimo Terzolo);
Investigation, S.P., A.C., V.B., F.C., C.S. (Carla Scaroni), C.S. (Chiara Simeoli), M.T. (Massimo Torlontano), S.C.,
G.A., A.S., P.M., L.S., B.A., S.D.C., P.P., G.D.F., L.C., P.L., G.R. and M.T. (Massimo Terzolo); Methodology, P.B.;
Project administration, M.T. (Massimo Terzolo); Resources, M.T. (Massimo Terzolo); Software, M.T. (Massimo
Terzolo); Supervision, M.T. (Massimo Terzolo); Validation, L.S. and P.P.; Visualization, S.P., G.R. and M.T. (Massimo
Terzolo); Writing—original draft, S.P., A.C. and M.T. (Massimo Terzolo); Writing—review and editing, S.P., A.C.,
V.B., F.C., C.S. (Carla Scaroni), C.S. (Chiara Simeoli), M.T. (Massimo Torlontano), S.C., G.A., A.S., P.M., L.S., B.A.,
S.D.C., P.P., P.B., G.D.F., L.C., P.L., G.R. and M.T. (Massimo Terzolo).
Funding: This research was funded by Associazione Italiana per la Ricerca sul Cancro, grant number IG17678.
Acknowledgments: We acknowledge HRA Pharma (Paris, France) for providing access to the Lysosafe®
Online database.
Conflicts of Interest: Puglisi Soraya has received a grant for scientific writing from HRA Pharma; Massimo
Terzolo has received research grants from HRA Pharma and Novartis, and advisory board honoraria from HRA
Pharma; the others authors have stated explicitly that there are no conflicts of interest in connection with this
article. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data;
in the writing of the manuscript, or in the decision to publish the results.
References
1. Crucitti, F.; Bellantone, R.; Ferrante, A.; Boscherini, M.; Crucitti, P. The Italian Registry for Adrenal Cortical
Carcinoma: Analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group.
Surgery 1996, 119, 161–170. [CrossRef]
2. Icard, P.; Goudet, P.; Charpenay, C.; Andreassian, B.; Carnaille, B.; Chapuis, Y.; Cougard, P.; Henry, J.F.;
Proye, C. Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French
Association of Endocrine Surgeons study group. World J. Surg. 2001, 25, 891–897. [CrossRef] [PubMed]
3. Bilimoria, K.Y.; Shen, W.T.; Elaraj, D.; Bentrem, D.J.; Winchester, D.J.; Kebebew, E.; Sturgeon, C. Adrenocortical
carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 2008, 113, 3130–3136.
[CrossRef] [PubMed]
4. Wängberg, B.; Khorram-Manesh, A.; Jansson, S.; Nilsson, B.; Nilsson, O.; Jakobsson, C.E.; Lindstedt, S.;
Odén, A.; Ahlman, H. The long-term survival in adrenocortical carcinoma with active surgical management
and use of monitored mitotane. Endocr. Relat. Cancer 2010, 17, 265–272. [CrossRef] [PubMed]
5. Amini, N.; Margonis, G.A.; Kim, Y.; Tran, T.B.; Postlewait, L.M.; Maithel, S.K.; Wang, T.S.; Evans, D.B.;
Hatzaras, I.; Shenoy, R.; et al. Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of
Postoperative Recurrence. Ann. Surg. Oncol. 2016, 23, 126–133. [CrossRef]
6. Fassnacht, M.; Dekkers, O.M.; Else, T.; Baudin, E.; Berruti, A.; de Krijger, R.; Haak, H.R.; Mihai, R.;
Assie, G.; Terzolo, M. European Society of Endocrinology Clinical Practice Guidelines on the management of
adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal
Tumors. Eur. J. Endocrinol. 2018, 179, G1–G46. [CrossRef]
7. Hermsen, I.G.; Fassnacht, M.; Terzolo, M.; Houterman, S.; den Hartigh, J.; Leboulleux, S.; Leboulleux, S.;
Daffara, F.; Berruti, A.; Chadarevian, R.; et al. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as
predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T
multicenter study. J. Clin. Endocrinol. Metab. 2011, 96, 1844–1851. [CrossRef]
8. Terzolo, M.; Baudin, A.E.; Ardito, A.; Kroiss, M.; Leboulleux, S.; Daffara, F.; Perotti, P.; Feelders, R.A.;
deVries, J.H.; Zaggia, B.; et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma
treated adjuvantly following radical resection. Eur. J. Endocrinol. 2013, 169, 263–270. [CrossRef]
9. Megerle, F.; Herrmann, W.; Schloetelburg, W.; Ronchi, C.L.; Pulzer, A.; Quinkler, M.; Beuschlein, F.; Hahner, S.;
Kroiss, M.; Fassnacht, M.; et al. Mitotane Monotherapy in Patients with Advanced Adrenocortical Carcinoma.
J. Clin. Endocrinol. Metab. 2018, 103, 1686–1695. [CrossRef]
J. Clin. Med. 2019, 8, 1850 9 of 9
10. Calabrese, A.; Basile, V.; Puglisi, S.; Perotti, P.; Pia, A.; Saba, L.; Berchialla, P.; Porpiglia, F.; Veltri, A.;
Volante, M.; et al. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at
high risk of recurrence. Eur. J. Endocrinol. 2019, 180, 387–396. [CrossRef]
11. Fassnacht, M.; Johanssen, S.; Quinkler, M.; Bucsky, P.; Willenberg, H.S.; Beuschlein, F.; Terzolo, M.;
Mueller, H.H.; Hahner, S.; Allolio, B.; et al. Limited prognostic value of the 2004 International Union Against
Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification. Cancer
2009, 115, 243–250. [CrossRef] [PubMed]
12. Rosendaal, F.R.; Cannegieter, S.C.; van der Meer, F.J.; Briët, E. A method to determine the optimal intensity of
oral anticoagulant therapy. Thromb. Haemost. 1993, 69, 236–239. [CrossRef] [PubMed]
13. Lausen, B.; Schumacher, M. Maximally Selected Rank Statistics. Biometrics 1992, 48, 73–85. [CrossRef]
14. Schteingart, D.E.; Motazedi, A.; Noonan, R.A.; Thompson, N.W. Treatment of adrenal carcinomas. Arch. Surg.
1982, 117, 1142–1146. [CrossRef]
15. Pommier, R.F.; Brennan, M.F. An eleven-year experience with adrenocortical carcinoma. Surgery 1992, 112,
963–970.
16. Bellantone, R.; Ferrante, A.; Boscherini, M.; Lombardi, C.P.; Crucitti, P.; Crucitti, F.; Favia, G.; Borrelli, D.;
Boffi, L.; Capussotti, L.; et al. Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188
cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997, 122, 1212–1218.
[CrossRef]
17. Schulick, R.D.; Brennan, M.F. Long-term survival after complete resection and repeat resection in patients
with adrenocortical carcinoma. Ann. Surg. Oncol. 1999, 6, 719–726. [CrossRef]
18. Berruti, A.; Grisanti, S.; Pulzer, A.; Claps, M.; Daffara, F.; Loli, P.; Mannelli, M.; Boscaro, M.; Arvat, E.;
Tiberio, G.; et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients with Radically Resected
Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab. 2017, 102, 1358–1365. [CrossRef]
19. Stigliano, A.; Chiodini, I.; Giordano, R.; Faggiano, A.; Canu, L.; Della Casa, S.; Loli, P.; Luconi, M.; Mantero, F.;
Terzolo, M. Management of adrenocortical carcinoma: A consensus statement of the Italian Society of
Endocrinology (SIE). J. Endocrinol. Investig. 2016, 39, 103–121. [CrossRef]
20. Terzolo, M.; Berruti, A. Adjunctive treatment of adrenocortical carcinoma. Curr. Opin. Endocrinol. Diabetes
Obes. 2008, 15, 221–226. [CrossRef]
21. Fassnacht, M.; Libé, R.; Kroiss, M.; Allolio, B. Adrenocortical carcinoma: A clinician’s update. Nat. Rev.
Endocrinol. 2011, 7, 323–335. [CrossRef] [PubMed]
22. Puglisi, S.; Perotti, P.; Cosentini, D.; Roca, E.; Basile, V.; Berruti, A.; Terzolo, M. Decision-making for
adrenocortical carcinoma: Surgical, systemic, and endocrine management options. Exp. Rev. Anticancer Ther.
2018, 18, 1125–1133. [CrossRef] [PubMed]
23. Kerkhofs, T.M.; Derijks, L.J.; Ettaieb, M.H.; Eekhoff, E.M.; Neef, C.; Gelderblom, H.; den Hartigh, J.;
Guchelaar, H.J.; Haak, H.R. Short-term variation in plasma mitotane levels confirms the importance of trough
level monitoring. Eur. J. Endocrinol. 2014, 171, 677–683. [CrossRef] [PubMed]
24. D’Avolio, A.; De Francia, S.; Basile, V.; Cusato, J.; De Martino, F.; Pirro, E.; Piccione, F.; Ardito, A.; Zaggia, B.;
Volante, M.; et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharm. Genom.
2013, 23, 293–300. [CrossRef] [PubMed]
25. Else, T.; Williams, A.R.; Sabolch, A.; Jolly, S.; Miller, B.S.; Hammer, G.D. Adjuvant therapies and patient
and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J. Clin.
Endocrinol. Metab. 2014, 99, 455–461. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
